20
nanotimes
Companies Facts
ment for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystalliza- tion and X-ray structural analysis, provides services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug meta- bolism and pharmacokinetics services.
A
http://www.amriglobal.com
pany Antisense Pharma presented current data from its ongoing clinical Phase I/II trial with intrave- nous monotherapy of trabedersen (AP 12009) for the treatment of patients with advanced pancreatic cancer (PanCa), malignant melanoma (MM), and colorectal carcinoma (CRC). During the oral presen- tation session ‘Developmental Therapeutics – Clinical Pharmacology and Immunotherapy’ Helmut Oettle, MD, PhD, Charité Medical Faculty of the Humboldt University of Berlin, coordinating investigator pointed out trabedersen’s encouraging safety and efficacy data: “These data suggest that trabedersen is safe and very well tolerated in systemic application – and quality of life is already a crucial factor in validation of new anti cancer drugs.” PanCa patients treated 2 nd-line with trabedersen (N=15) reached a median overall survival (mOS) of 6.9 months which is com- parable to best available chemotherapy (mOS 5 – 6 months, historical data) 1. Additionally, patients treated 2nd-line with the dose 140 mg/m2/d (N=9) showed an encouraging survival benefit: their mOS was 13.4 months – in comparison to best available chemotherapy.
A
t the international cancer congress ASCO 2011 in Chicago, USA, the biopharmaceutical com-
MRI (NASDAQ: AMRI) and Proteros Biostruc- tures GmbH (Proteros) have signed an agree-
“Since there is no approved 2nd-line treatment for PanCa patients in the USA and Europe, we are con- fident that our innovative immunostimulatory me- dication trabedersen will help to prolong survival in advanced pancreatic cancer patients.” adds Hubert Heinrichs, MD, PhD, Chief Medical Officer at Anti- sense Pharma.
http://www.antisense-pharma.com http://chicago2011.asco.org/Home.aspx http://abstract.asco.org/AbstView_102_74007.html
Commission for a proposed initial public offering of its common stock. Goldman, Sachs & Co. and Mor- gan Stanley & Co. LLC will act as joint book-running managers for the offering. The number of shares to be sold in the proposed offering and the price range of the proposed offering have not yet been deter- mined.
A
In October 2011, BASF Venture Capital, Germany, has led a $21.5 million round of investment in Aspen Aerogels, Inc. Aspen supplies reinforced, nanopo- rous aerogel insulation products that are up to five times more effective than other insulation mate- rials. The company‘s solutions enable customers to conserve energy in a variety of industries including building and construction, chemicals, transportation and oil and gas.
Other investors are RockPort Capital, Tenaya Ca- pital, Reservoir Capital Group, Arcapita Ventures
spen Aerogels, Inc., has filed a registration statement with the Securities and Exchange
11-06/07 :: June/July 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111